Gene:
FMO3
flavin containing monooxygenase 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1736557 171080080G>A, 22568722G>A, 25063G>A, 769G>A, Val257Met
G > A
Missense
Val257Met
No VIP available CA VA
rs2266780 171083242A>G, 22571884A>G, 28225A>G, 923A>G, Glu308Gly
A > G
Missense
Glu308Gly
No VIP available No Clinical Annotations available VA
rs2266782 171076966G>A, 21949G>A, 22565608G>A, 472G>A, Glu158Lys
G > A
Missense
Glu158Lys
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA166

Details

Cytogenetic Location: chr1 : q24.3 - q24.3
GP mRNA Boundary: chr1 : 171060018 - 171086959
GP Gene Boundary: chr1 : 171050018 - 171089959
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Nicotine Pathway, Pharmacokinetics
    Summary of nicotine metabolism in human liver cell.
  1. Tamoxifen Pathway, Pharmacokinetics
    Tamoxifen metabolism in the liver.

External Pathways

Links to non-PharmGKB pathways.

  1. FMO oxidizes nucleophiles - (Reactome via Pathway Interaction Database)
  2. N-oxidation of nitrogen compounds - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Neoplasms

Publications related to FMO3: 11

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An atlas of genetic influences on human blood metabolites. Nature genetics. 2014. Shin So-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. Pharmacogenetics and genomics. 2014. Chenoweth Meghan J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013. Söderberg Mao Mao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. The pharmacogenomics journal. 2012. Söderberg M M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Visscher Henk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. The pharmacogenomics journal. 2011. Schröder A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenetics and genomics. 2010. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis. Pharmacogenomics. 2009. Mao Mao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacology & therapeutics. 2008. Hines Ronald N. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. Pharmacogenetics. 2004. Mayatepek Ertan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. Chemical research in toxicology. 1992. Cashman J R, et al. PubMed

LinkOuts

Entrez Gene:
2328
OMIM:
136132
602079
UCSC Genome Browser:
NM_006894
RefSeq RNA:
NM_001002294
NM_006894
RefSeq Protein:
NP_001002294
NP_008825
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NG_012690
NT_004487
NW_001838533
NW_926128
UniProtKB:
FMO3_HUMAN (P31513)
Q53FW5_HUMAN (Q53FW5)
Ensembl:
ENSG00000007933
GenAtlas:
FMO3
GeneCard:
FMO3
MutDB:
FMO3
ALFRED:
LO041718V
HuGE:
FMO3
Comparative Toxicogenomics Database:
2328
ModBase:
P31513
HumanCyc Gene:
HS00223
HGNC:
3771

Common Searches